$73.54
+1.12
(+1.55%)▲
0.67%
Downside
Day's Volatility :4.02%
Upside
3.38%
38.13%
Downside
52 Weeks Volatility :46.4%
Upside
13.37%
Period | Intra-cellular Therapies, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 7.5% | 5.1% | 0.0% |
6 Months | 10.22% | 4.9% | 0.0% |
1 Year | 27.76% | 16.6% | 0.0% |
3 Years | 116.36% | 13.2% | -22.3% |
Market Capitalization | 7.8B |
Book Value | $10.84 |
Earnings Per Share (EPS) | -0.87 |
PEG Ratio | 0.0 |
Wall Street Target Price | 95.84 |
Profit Margin | -14.93% |
Operating Margin TTM | -17.18% |
Return On Assets TTM | -6.91% |
Return On Equity TTM | -9.63% |
Revenue TTM | 564.5M |
Revenue Per Share TTM | 5.75 |
Quarterly Revenue Growth YOY | 45.7% |
Gross Profit TTM | 95.2M |
EBITDA | -112.0M |
Diluted Eps TTM | -0.87 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.67 |
EPS Estimate Next Year | 0.72 |
EPS Estimate Current Quarter | -0.19 |
EPS Estimate Next Quarter | -0.14 |
What analysts predicted
Upside of 30.32%
Sell
Neutral
Buy
Intra-cellular Therapies, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Intra-cellular Therapies, Inc. | -0.12% | 10.22% | 27.76% | 116.36% | 611.91% |
![]() Neurocrine Biosciences Inc. | -16.62% | -11.2% | 10.78% | 28.21% | 20.17% |
![]() Haleon Plc Spon Ads | 7.49% | 20.82% | 28.48% | 39.41% | 39.41% |
![]() Zoetis Inc. | 2.41% | 4.25% | 0.77% | -8.94% | 49.4% |
![]() Viatris Inc. | -0.79% | -8.6% | 12.7% | -23.12% | -31.03% |
![]() Catalent, Inc. | 0.82% | 6.48% | 22.57% | -57.47% | 16.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Intra-cellular Therapies, Inc. | NA | NA | 0.0 | -0.67 | -0.1 | -0.07 | NA | 10.84 |
![]() Neurocrine Biosciences Inc. | 36.53 | 36.53 | 0.27 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
![]() Haleon Plc Spon Ads | 33.32 | 33.32 | 1.47 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
![]() Zoetis Inc. | 36.6 | 36.6 | 2.61 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
![]() Viatris Inc. | 224.4 | NA | 0.07 | 2.68 | -0.03 | 0.03 | 0.04 | 16.36 |
![]() Catalent, Inc. | 211.02 | NA | 2.87 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Intra-cellular Therapies, Inc. | Buy | $7.8B | 611.91% | NA | -14.93% |
![]() Neurocrine Biosciences Inc. | Buy | $12.2B | 20.17% | 36.53 | 16.0% |
![]() Haleon Plc Spon Ads | Buy | $47.1B | 39.41% | 33.32 | 9.66% |
![]() Zoetis Inc. | Buy | $85.7B | 49.4% | 36.6 | 26.29% |
![]() Viatris Inc. | Hold | $13.5B | -31.03% | 224.4 | -4.24% |
![]() Catalent, Inc. | Hold | $10.9B | 16.16% | 211.02 | -23.81% |
Insights on Intra-cellular Therapies, Inc.
Revenue is up for the last 18 quarters, 882.51K → 161.38M (in $), with an average increase of 23.3% per quarter
Netprofit is down for the last 2 quarters, -15.24M → -16.21M (in $), with an average decrease of 6.4% per quarter
In the last 1 year, Haleon Plc Spon Ads has given 28.5% return, outperforming this stock by 0.7%
FMR Inc
Vanguard Group Inc
BlackRock Inc
Wasatch Advisors LP
venBio Select Advisor LLC
Bellevue Group AG
Intra-cellular Therapies, Inc.’s price-to-earnings ratio stands at None
Read Moreintra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
Organization | Intra-cellular Therapies, Inc. |
Employees | 610 |
CEO | Dr. Sharon Mates Ph.D. |
Industry | Health Technology |